Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study is designed to investigate the effects of a 12 week course of intravenous QAX576
6mg/kg every 4 weeks in reducing the number of eosinophils in the esophagus of EoE patients
by 75% or greater when compared with baseline.